新华鲜报丨“药篮子”上新！2025年医保商保“双目录”发布

Core Insights - The annual adjustment of the National Medical Insurance Drug List has significant implications for public health and access to medications, with 114 new drugs added to the insurance list and 19 new drugs included in the commercial insurance innovation drug list [1][3] Group 1: Drug Inclusion and Categories - The new insurance list includes 114 drugs, focusing on clinical needs and affordability, with 36 cancer drugs, 12 chronic disease medications, 13 anti-infective drugs, and 10 rare disease treatments [3] - Notable additions include life-saving drugs such as Alpelisib for triple-negative breast cancer and Irinotecan liposome for pancreatic cancer, as well as chronic disease medications like Icosapent ethyl and Tirzepatide [3] Group 2: Innovation and Market Impact - The adjustment features 50 innovative drugs, including recently approved medications like the flu treatment Baloxavir marboxil, indicating a trend towards faster access to innovative therapies [4] - The total number of drugs in the National Medical Insurance Directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [4] Group 3: Commercial Insurance Support - The commercial insurance innovation drug list includes high-value innovative drugs such as CAR-T therapies and treatments for rare diseases, totaling 19 new drugs [5] - The policy provides support for these drugs, allowing them to be excluded from basic insurance self-payment rates and monitoring for alternative products, enhancing patient access to necessary medications [5] Group 4: Industry Response and Future Outlook - Pharmaceutical companies view the directory as a guiding framework, encouraging them to focus on unmet medical needs and invest in research and development [7] - The National Medical Insurance Directory has added 949 drugs over the past eight years, with insurance funds covering significant expenditures, driving market growth and innovation [8] - The new drug lists are set to be implemented on January 1, 2026, marking a pivotal moment for the pharmaceutical industry in China [8]